You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020161025
Dec 202050010
Jan 20215409
Feb 2021132016
Mar 2021142015
Apr 2021168018
May 202133019
Jun 20210024
Jul 20210017
Aug 20210012
Sep 20210017
Oct 202192035
Nov 2021112037
Dec 202145013
Jan 20224809
Feb 2022104016
Mar 202234019
Apr 202276012
May 20229409
Jun 202298019
Jul 202260017
Aug 202270018
Sep 20224809
Oct 202264015
Nov 20225004
Dec 20225607
Jan 2023182017
Feb 2023132019
Mar 202310806
Apr 202360011
May 2023106020
Jun 20234003
Jul 20237209
Aug 202356021
Sep 20233402
Oct 20234203
Nov 20233602
Dec 20237603
Jan 20242800
Feb 20243801
Mar 20246203
Apr 20244205
May 20243202
Jun 20246304
Jul 20243607
Aug 20242702
Sep 20242003
Oct 20242403
Nov 20242002
Dec 20241008
Jan 202518013
Feb 2025807
Mar 2025203
Apr 2025003
May 2025003
Jun 2025304
Total31680610